Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
McDaniel, S
Circulation 127, 7485
Pfizer is way behind the GLP-1 pack Pfizer has a problem when it comes to GLP-1 weight-loss drugs
For a category that has attracted significant FDA scrutiny in 2026, that level of structural transparency is not a minor detail - it is a baseline expectation that fewer platforms meet than the volume of advertising in this space would suggest
Before prescribing, clinicians should confirm appropriate indicationseither inadequately controlled type 2 diabetes or obesity with BMI 30 kg/m (or 27 kg/m with weight-related comorbidities such as hypertension or dyslipidemia)
US$ 23.97
US$ 23.49
US$ 29.97
US$ 28.87
US$ 22.77
US$ 21.29
US$ 27.89
US$ 20.93
